FY2025 EPS Estimates for Repligen Lifted by William Blair

Repligen Co. (NASDAQ:RGEN) – Equities research analysts at William Blair boosted their FY2025 earnings per share (EPS) estimates for Repligen in a research report issued to clients and investors on Wednesday, April 30th. William Blair analyst M. Larew now forecasts that the biotechnology company will post earnings per share of $1.68 for the year, up from their previous forecast of $1.67. The consensus estimate for Repligen’s current full-year earnings is $1.72 per share. William Blair also issued estimates for Repligen’s Q3 2026 earnings at $0.58 EPS and FY2026 earnings at $2.28 EPS.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings data on Tuesday, April 29th. The biotechnology company reported $0.39 EPS for the quarter, beating analysts’ consensus estimates of $0.35 by $0.04. The firm had revenue of $169.17 million for the quarter, compared to the consensus estimate of $163.65 million. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. The firm’s revenue was up 10.4% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.28 EPS.

A number of other equities analysts also recently commented on the company. Evercore ISI initiated coverage on Repligen in a research note on Tuesday, March 18th. They issued an “in-line” rating and a $155.00 target price for the company. TD Cowen assumed coverage on Repligen in a report on Monday, February 10th. They issued a “buy” rating and a $200.00 price objective for the company. StockNews.com raised Repligen from a “sell” rating to a “hold” rating in a research note on Monday, April 28th. Wolfe Research raised Repligen from a “peer perform” rating to an “outperform” rating and set a $160.00 price target for the company in a research note on Tuesday. Finally, JPMorgan Chase & Co. cut their price objective on shares of Repligen from $200.00 to $190.00 and set an “overweight” rating on the stock in a research note on Tuesday. Six equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $173.25.

Repligen Stock Up 3.1 %

Shares of Repligen stock opened at $141.51 on Friday. The business has a 50-day moving average price of $137.82 and a 200 day moving average price of $145.81. Repligen has a fifty-two week low of $102.97 and a fifty-two week high of $182.52. The firm has a market cap of $7.95 billion, a P/E ratio of -277.47, a P/E/G ratio of 4.54 and a beta of 1.27. The company has a quick ratio of 8.76, a current ratio of 10.44 and a debt-to-equity ratio of 0.26.

Insider Transactions at Repligen

In other news, Director Margaret Pax bought 250 shares of the stock in a transaction that occurred on Monday, March 17th. The shares were acquired at an average cost of $150.69 per share, for a total transaction of $37,672.50. Following the purchase, the director now owns 1,043 shares of the company’s stock, valued at $157,169.67. This represents a 31.53 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 1.20% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Repligen

A number of institutional investors have recently made changes to their positions in RGEN. Price T Rowe Associates Inc. MD lifted its holdings in shares of Repligen by 11.6% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 7,136,054 shares of the biotechnology company’s stock worth $1,027,165,000 after buying an additional 743,815 shares during the last quarter. Point72 Asset Management L.P. raised its stake in shares of Repligen by 183.1% in the fourth quarter. Point72 Asset Management L.P. now owns 918,623 shares of the biotechnology company’s stock valued at $132,227,000 after purchasing an additional 594,189 shares in the last quarter. Groupama Asset Managment increased its holdings in Repligen by 12,321.0% in the 4th quarter. Groupama Asset Managment now owns 403,932 shares of the biotechnology company’s stock valued at $58,142,000 after buying an additional 400,680 shares during the period. Alyeska Investment Group L.P. acquired a new position in shares of Repligen in the 4th quarter valued at $53,428,000. Finally, Raymond James Financial Inc. bought a new position in shares of Repligen during the 4th quarter worth about $52,492,000. 97.64% of the stock is currently owned by institutional investors.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.